This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
Momordica charantia
This herb is NOT recommended during pregnancy due to potential risks to the developing fetus.
Consult your healthcare provider before use.
Metabolic application of bitter melon; polypeptide-P acts as plant insulin; charantin increases glucose uptake in cells; vicine activates AMPK for muscle glucose utilization.
Metabolic application of bitter melon; polypeptide-P acts as plant insulin; charantin increases glucose uptake in cells; vicine activates AMPK for muscle glucose utilization. Key active compounds include Charantin, Polypeptide-P, Vicine.
Charantin, along with Polypeptide-P and Vicine, are the primary bioactive compounds in Bitter Melon Metabolic. The specific pharmacological pathways require further study, though traditional use supports its efficacy.
AMPK activation for glucose utilization
Supported by clinical evidence; more large-scale trials would strengthen findings
Insulin sensitizer and secretagogue
Supported by clinical evidence; more large-scale trials would strengthen findings
Anti-obesity effects
Limited clinical evidence; primarily supported by traditional use and preliminary studies
Blood sugar management in tropical traditional medicine worldwide
Based on traditional use; clinical evidence limited
Pancreatic tonic
Based on traditional use; clinical evidence limited
Anti-obesity and appetite reduction
Based on traditional use; clinical evidence limited
Found an error or have a correction for Bitter Melon Metabolic?
Report an Issue →